BACE1 and Alzheimer disease: While BACE1 inhibitors have been thoroughly investigated as candidate therapeutics during the symptomatic and/or pre-symptomatic stages in patients with AD, all such clinical trials were halted due to a lack of efficacy and/or safety concerns (18, 19).